Jade Biosciences Announces Conference Participation
Jade Biosciences, Inc. (NASDAQ: JBIO), a notable player in biotechnology, specializes in advanced therapies aimed at tackling autoimmune diseases. The company has recently revealed its participation in several noteworthy upcoming conferences that are expected to showcase its innovative research and development efforts.
Key Conferences on the Horizon
This year, Jade will be taking part in the Cantor Global Healthcare Conference, the Stifel Virtual Immunology and Inflammation Forum, and the 11th Annual World Medical Innovation Forum. These events present valuable platforms for Jade to connect with industry experts, share insights, and discuss the future of healthcare solutions in immunology.
Cantor Global Healthcare Conference
From September 3 to 5, Jade will be featured prominently at the Cantor Global Healthcare Conference. The management team will partake in a fireside chat scheduled for September 3 at 3:20 p.m. ET, where discussions will likely revolve around the company’s groundbreaking approaches and therapies that they are developing.
Stifel Virtual Immunology and Inflammation Forum
Continuing their active engagement, Jade is set to join the Stifel Virtual Immunology and Inflammation Forum on September 15 and 16. The highlight will be another fireside chat on September 16 at 1:00 p.m. ET, offering a chance for deeper engagement with investors and industry leaders about latest advancements.
World Medical Innovation Forum Participation
Moreover, Jade Biosciences is also participating in the 11th Annual World Medical Innovation Forum, hosted by Bank of America and Mass General Brigham from September 15 to 17. They will be featured on a panel focused on 'Immunology – Creating the Next Blockbuster in I&I' on September 16 at 4:40 p.m. ET, underscoring their commitment to leading innovations in immunology.
Opportunities for Investors
During these conferences, members of the Jade management team will conduct one-on-one investor meetings, providing an exclusive opportunity for interested parties to discuss the company’s future and investment potential directly. These sessions are designed to give potential investors insights into the promising developments Jade is pursuing.
Company’s Vision
About Jade Biosciences, they are dedicated to creating targeted therapies for autoimmune diseases. Their leading product candidate, JADE101, focuses on transforming treatment approaches for immunoglobulin A nephropathy. In addition, Jade is advancing other projects like JADE201 and an undisclosed program, each in various stages of preclinical development.
Furthermore, Jade was established on the foundation of proprietary assets licensed from Paragon Therapeutics. Their journey represents a meaningful shift towards innovative therapies that address critical needs in healthcare.
Contact Information
For media inquiries and further details about their participation in the conferences, interested individuals can reach out to Priyanka Shah at Media@JadeBiosciences.com or IR@JadeBiosciences.com. You can also contact them at 908-447-6134.
Frequently Asked Questions
What is Jade Biosciences focused on?
Jade Biosciences is focused on developing targeted therapies for autoimmune diseases.
Which conferences will Jade Biosciences attend?
Jade will participate in the Cantor Global Healthcare Conference, the Stifel Virtual Immunology and Inflammation Forum, and the World Medical Innovation Forum.
What is the significance of the upcoming conferences for Jade?
These conferences present opportunities to share their innovations and engage with investors and industry experts.
How can investors meet with Jade management?
Jade will host one-on-one meetings for investors during these conferences, allowing for direct discussions.
Who can be contacted for more information about Jade?
Priyanka Shah, reachable at Media@JadeBiosciences.com or 908-447-6134, can provide further information.
